Herman Clements, MD
Psychiatry · Searcy, ARNPI 1427019371
Payments from drug & device makers
Across 660 payments — averaging $283.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$147K
- Tris Pharma Inc$27K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
- Sunovion Pharmaceuticals Inc.$951
- Johnson & Johnson$680
- Otsuka America Pharmaceutical, Inc.$602
- plus $3K from 16 others
What the payments were for
- Speaking & faculty fees$168,82090%
- Travel & lodging$8,2334%
- Food & beverage$9,4605%
- Education$2960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 326 | $146,690 |
| Tris Pharma Inc | 50 | $27,219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $8,104 |
| Sunovion Pharmaceuticals Inc. | 39 | $951 |
| Johnson & Johnson | 46 | $680 |
| Otsuka America Pharmaceutical, Inc. | 33 | $602 |
| Teva Pharmaceuticals USA, Inc. | 17 | $374 |
| Merz North America, Inc. | 1 | $279 |
| Lundbeck LLC | 16 | $279 |
| Neurocrine Biosciences, Inc. | 15 | $271 |
| Supernus Pharmaceuticals, Inc. | 14 | $268 |
| Ironshore Pharmaceuticals Inc. | 12 | $220 |
| Alkermes, Inc. | 12 | $208 |
| Vanda Pharmaceuticals Inc. | 12 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $133 |
| Sun Pharmaceutical Industries Inc. | 4 | $80 |
| Eisai Inc. | 5 | $75 |
| Almatica Pharma LLC | 3 | $64 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Neuronetics, Inc. | 2 | $25 |
| Livanova USA, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$140,969
- Dyanavel XR$26,686
- Quillivant$26,686
- Quillichew ER$26,686
- CAPLYTA$7,350
- LATUDA$420
- XEOMIN$279
How this compares
$186,809 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 30 | $300,289 |
| IngrezzaValbenazine Tosylate | 20 | $175,153 |
| VraylarCariprazine Hcl | 55 | $92,517 |
| CaplytaLumateperone Tosylate | 43 | $73,337 |
| RexultiBrexpiprazole | 43 | $70,379 |
| BelsomraSuvorexant | 84 | $38,637 |
| Paliperidone ErPaliperidone | 31 | $18,426 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 431 | $16,782 |
| TrintellixVortioxetine Hydrobromide | 22 | $13,964 |
| LithobidLithium Carbonate | 12 | $12,583 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $11,921 |
| QuviviqDaridorexant Hcl | 24 | $11,537 |
| Quetiapine Fumarate | 381 | $7,842 |
| DayvigoLemborexant | 21 | $6,877 |
| Lurasidone Hcl | 37 | $6,242 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $374 | $300,28930 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $271 | $175,15320 claims |
| AbbVieVraylar | $146,690 | $92,51755 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $8,104 | $73,33743 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $602 | $70,37943 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $133 | $25,88653 claims |
| Eisai Inc.Dayvigo | $75 | $6,87721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Searcy
- Ronald WautersSearcy$204K
- David DraneySearcy$9K
- Robert StrayhanSearcy$6K
- Brian HowardSearcy$4K
- Jacqueline KoichiSearcy$3K
- Leslie SmithLittle Rock$7.9M
- Gintaras AukstuolisLittle Rock$6.6M
- Robert BillingsleyFayetteville$5.9M
- Paul WylieLittle Rock$3.4M
- Robert WootenPine Bluff$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.